Pertuzumab biosimilar(EirGenix)

帕妥珠单抗生物类似药（台康生技）

Report date: 2025/10/15 20:01:42

Base Information

Drug NamePertuzumab biosimilar(EirGenix)

Drug Alias NamePertuzumabum biosimilar(EirGenix)培妥珠单抗生物类似药（台康生技）Anti-2C4 monoclonal antibody(EirGenix)珀妥珠单抗生物类似药（台康生技）帕妥株单抗生物类似药（台康生技） +[7]

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanizedBiologics > Biosimilar

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 antagonists

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsBreast Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesTaiwanGermany

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesEirgenix Inc

China Registration ClassN/A

Active CompaniesEirgenix Inc

Inactive CompaniesN/A

Active IndicationsBreast Neoplasms

Inactive IndicationsN/A

ATC CodeN/A